Company news

Revive Therapeutics Ltd. news in 2026

Revive Therapeutics Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases

September 15, 2026

Revive Therapeutics Announces Proposed Shares for Debt Settlement

August 19, 2026

Revive Therapeutics Reports Grant of Options

August 14, 2026

Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study

August 12, 2026

Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

July 15, 2026

Revive Therapeutics Announces Proposed Private Placement

June 26, 2026

Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures

May 20, 2026

Decks in 2026